| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
STAAR Surgical Company$22.95
-0.43 (-1.84%)
F 16Pipeline Score MedTech · Commercial
Market Cap
1.62 B
EPS
-0.42
P/E Ratio
-
Value Trade
11.17 M
SEC Financials
Q2 2026Dilution Risk
Revenue
93.52 M
R&D Expenses
9.93 M
Operating CF
-21.70 M
Total Assets
451.12 M
Total Liabilities
98.75 M
Equity
352.37 M
D/E Ratio
12,345
1.47 %
Week
29.67 %
1 Month
82.72 %
3 Month
18.03 %
6 Month
-74.02 %
5 Year
140.52 %
All Time
Cash Data
Cash Position
163.89 M
Monthly Burn
7.23 M
Runway
20.2 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
725.12 K
52 Week Range
15.59 - 35.87
% held by Insiders
39.76 %
% held by Institutions
75.28 %
Enterprise Value
1.49 B
Total Shares
49.80 M
Short %
17.05 %
Float Shares
29.88 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 12%
Micro Cap (rank 804 of 913)
Percentile RankSTAAR Surgical Company has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STAA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
STAA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STAA▼ -8.8%on this news
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026
STAAR Surgical Company has reported strong preliminary net sales for the second quarter of 2026, exceeding expectations. This announcement comes ahead of their quarterly earnings report scheduled for August 12, 2026. The company maintains its position as a leader in the phakic IOLs market with its EVO family of lenses.
Read more →STAASTAAR Surgical Announces Participation in Upcoming Investor Conferences
STAAR Surgical has announced its participation in several upcoming investor conferences. The details regarding the specific conferences and the topics to be discussed were not provided in the article. This participation may present opportunities for the company to engage with investors and stakeholders.
Read more →STAASTAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
STAAR Surgical has reported its financial results for the first quarter of 2026 and issued a letter to shareholders. The report includes key financial metrics and insights into the company's performance during this period. Further details on the company's strategic direction and future outlook may be provided in the shareholder letter.
Read more →STAAReconciliation of Non-GAAP Financial Measure Constant Currency Sales (in 000's) Unaudited Three Months Ended Three Months Ended As Reported Constant Currency Sales
STAAR Surgical Company reported first quarter 2026 results, highlighting a record net sales of $93.5 million, a 119.6% year-over-year increase. The company returned to profitability with a net income of $5.2 million, reflecting improved margins and operational effectiveness. Notably, the introduction of the EVO+ ICL in China has shown strong early demand, positioning the company favorably amidst optimistic growth projections. While challenges remain, including geopolitical uncertainties, STAAR is leveraging its market leadership in lens-based refractive surgery for future growth.
Read more →STAASTAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
STAAR Surgical has announced it will host its first quarter 2026 earnings results call and webcast on May 13, 2026. This event will provide stakeholders with insights into the company's financial performance for the quarter. Further details regarding the call will likely be shared closer to the date.
Read more →STAASTAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
STAAR Surgical has announced its preliminary net sales for the first quarter of 2026. The announcement highlights the company's financial performance but lacks detailed insights into specific sales figures or growth metrics. The news is presented without any significant positive or negative implications.
Read more →STAASTAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
STAAR Surgical has announced the sale of over 4 million Implantable Collamer Lenses (ICLs) globally, highlighting a significant shift from laser-based vision correction to lens-based solutions. This milestone reflects the increasing preference among patients and surgeons for minimally invasive procedures that preserve corneal integrity. The company's EVO ICL platform continues to gain traction, supported by expanded regulatory indications and positive clinical outcomes.
Read more →STAA▲ +8.5%on this newsshared move
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026
STAAR Surgical Company will announce its financial results for the fourth quarter and fiscal year 2025 on March 3, 2026. An earnings call and webcast will follow at 5:30 p.m. ET to discuss these results and the company's progress. The event underscores STAAR's commitment to transparency with investors.
Read more →STAA▲ +8.4%on this news
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
The FDA has expanded the age indication for EVO ICL, allowing its use for patients aged 21 to 60. This change increases the potential market by nearly 8 million patients and comes alongside positive long-term safety data from clinical trials. The refractive vision correction market is shifting away from laser procedures, with EVO ICL gaining popularity among patients with high myopia.
Read more →STAASTAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
STAAR Surgical has appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 1, 2026. The Board of Directors expressed confidence in their leadership during this transitional period. A Search Committee has been formed to find a permanent CEO, engaging both internal and external candidates. Foust and Andrews bring extensive experience to their roles.
Read more →STAASTAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
STAAR Surgical has entered into a cooperation agreement with Broadwood Partners, resulting in the appointment of new board members. The agreement led to the resignation of STAAR's Chair and CEO, although the CEO will remain until January 2026. The board aims to enhance profitability and long-term value creation.
Read more →STAA▼ -6.9%on this news
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders STAAR Intends to Terminate Alcon Merger Agreement
STAAR Surgical Company announced preliminary results indicating that the necessary stockholder votes to approve its merger agreement with Alcon were not received. As a result, STAAR intends to terminate the agreement and will remain a publicly traded company under the ticker symbol STAA. CEO Stephen Farrell expressed respect for the vote's outcome and commitment to working with stockholders to enhance STAAR's performance as an independent entity, underscoring the company's focus on maximizing stockholder value.
Read more →STAASTAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
STAAR Surgical Company has urged its stockholders to vote in favor of the merger with Alcon Inc., which offers a cash payment of $30.75 per share. This offer is a significant premium compared to recent stock valuations. The company warns that Broadwood's attempts to derail the merger are misleading and could harm stockholder interests. The vote will take place during a virtual meeting on December 19, 2025.
Read more →STAASTAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
STAAR Surgical has issued a statement to counter misinformation regarding its go-shop process amid a pending merger with Alcon. The company asserts that allegations from Broadwood Partners about a credible buyer are false. STAAR emphasizes its commitment to maximizing shareholder value and encourages stockholders to accept Alcon's cash offer, which represents a significant premium.
Read more →STAABroadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
Broadwood Partners has publicly opposed STAAR Surgical's proposed acquisition by Alcon, citing a flawed process and lack of shareholder consideration. A dissenting board member's vote against the deal reflects broader concerns among shareholders and proxy advisory firms. Broadwood argues that the deal undervalues STAAR, especially given recent improvements in the company's performance and sector valuations.
Read more →STAA▼ -7.2%on this newsshared move
STAAR Surgical Announces Expiration of Go-Shop Period No Competing Acquisition Proposals Received Results of Go-Shop Process Validate the Effectiveness of the STAAR Board's Process Now is the Right Time to Sell the Busin
STAAR Surgical announced the expiration of its go-shop period related to the merger with Alcon Inc., revealing that no competing acquisition proposals were received. The board engaged with 21 parties, of which only two signed non-disclosure agreements, signaling limited interest from potential bidders. This outcome supports the board's process in selecting Alcon as the buyer, indicating that the strategic decision to sell was timely and well-founded. CEO Stephen Farrell emphasized the board's experience in navigating the sale process and addressing prior claims of ignored buyer interest.
Read more →STAASTAAR Surgical Announces Amendments to Alcon Merger Agreement 30-Day Go-Shop Period to Actively Solicit Other Third-Party Proposals No Termination Fee Payable to Alcon if STAAR Terminates Merger Agreement to Accept a Sup
STAAR Surgical has announced amendments to its merger agreement with Alcon, introducing a 30-day go-shop period that allows STAAR to solicit third-party proposals. This move aims to maximize the value for STAAR stockholders by enabling them to receive updated valuations based on recent financial results. Under the revised terms, STAAR will not incur a termination fee if it decides to accept a superior offer. Additionally, Alcon will engage with STAAR stockholders to gather insights supporting the merger proposal while the special meeting to vote on the merger has been postponed to December 19, 2025.
Read more →STAASTAAR Surgical Reports Third Quarter 2025 Results
STAAR Surgical Company reported its third quarter 2025 results, highlighting net sales of $94.7 million, a 6.9% increase year-over-year. The financial performance was bolstered by a significant payment from a previous ICL shipment. Despite growth in gross margin and adjusted EBITDA, the company experienced a decline in net income and faced reduced orders from distributors in China. The company will not hold a conference call due to its pending acquisition by Alcon Inc.
Read more →STAA▲ +5.7%on this news
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon STAAR Special Meeting of Stockholders Postponed to
STAAR Surgical Company has postponed its Special Meeting of Stockholders, originally scheduled for November 6, 2025, to December 3, 2025, to allow for ongoing discussions regarding its merger agreement with Alcon. The record date for stockholders eligible to vote has been set for October 24, 2025. This delay highlights the complexities of the proposed merger and the importance of ensuring all stakeholder interests are fully considered before moving forward.
Read more →STAA▲ +8.3%on this newsshared move
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders GENEVA &
Alcon and STAAR Surgical have announced the adjournment of STAAR's Special Meeting of Stockholders, initially set for October 23, 2025, in relation to their merger agreement. The meeting has been rescheduled for November 6, 2025, allowing stockholders additional time to consider their votes. This decision comes amid the ongoing processes related to the proposed merger and the filing of relevant materials with the SEC.
Read more →STAASTAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
STAAR Surgical Company announced preliminary net sales results for the third quarter of 2025, indicating that $25.9 million in net sales related to previous shipments were recognized. Despite this positive development, the company faced challenges as total sales for the first nine months of the year were down compared to the previous period due to distributors in China reducing their inventory. The firm is preparing for a special meeting of stockholders to vote on a proposed merger with Alcon, which introduces additional uncertainties.
Read more →STAAAdditional Information About the Merger and Where to Find It This presentation relates to the proposed transaction (the "Alcon merger") involving STAAR Surgical Company ("STAAR", "us" or "our"), Alcon Research, LLC, a De
STAAR Surgical Company is in the process of a proposed merger with Alcon Research, LLC, designed to provide enhanced value for STAAR's stockholders. The board believes this all-cash offer of $28.00 per share represents a significant premium and is a more favorable option than STAAR could achieve independently. The board conducted a thorough assessment of various strategic alternatives before reaching the decision to merge. However, there are concerns regarding STAAR's ongoing operational challenges and scrutiny from external stakeholders.
Read more →STAASTAAR Surgical Reports Second Quarter 2025 Results
STAAR Surgical Company reported its second quarter 2025 financial results, revealing a significant 55% decline in net sales year-over-year, primarily driven by reduced channel inventory in China. Despite a slight 10% increase in net sales excluding China, the overall performance showed a net loss of $16.8 million versus a profit of $7.4 million last year. Operating expenses decreased, reflecting cost optimization efforts, but the company incurred significant restructuring charges. The company also announced that it would not hold a conference call due to a pending acquisition by Alcon Inc.
Read more →STAA▲ +46.1%on this newsshared move
Alcon Agrees to Acquire STAAR Surgical STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon s l
Alcon has announced a definitive agreement to acquire STAAR Surgical for $28 per share, representing a 59% premium to STAAR's recent stock price. This acquisition aims to enhance Alcon's offerings in surgical vision correction, particularly for patients with moderate to high myopia. The transaction, valued at approximately $1.5 billion, is expected to close within six to twelve months, pending regulatory and shareholder approvals. Both companies' boards have unanimously approved the merger, emphasizing its potential benefits for shareholders.
Read more →STAASTAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer Forms Capital Stewardship Committee of the Board of Directors LAKE FOREST, CA –
STAAR Surgical has appointed Deborah Andrews as Chief Financial Officer, effective June 25, 2025, after previously serving in that role multiple times. The company also established a Capital Stewardship Committee to enhance its financial strategies and capital management, chaired by Board member Lilian Y. Zhou. This initiative aims to guide the company's growth prospects and strengthen shareholder returns. The announcement signifies confidence in Andrews's leadership as the company navigates future financial objectives.
Read more →STAAThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for
The investor presentation for STAA, set for June 2025, outlines forward-looking statements regarding various aspects of the company's operations and market conditions. It emphasizes expectations for financial performance, regulatory approvals, and procedural demand while noting potential challenges such as economic disruptions and competition. The presentation adheres to the safe harbor provisions, clearly stating risks that could materially affect actual results. Additionally, it includes non-GAAP financial information to aid investors in evaluating the company's performance.
Read more →STAA▲ +5.1%on this news
STAAR Surgical Announces $30 Million Share Repurchase Authorization
STAAR Surgical has authorized a $30 million share repurchase program, a move that reflects the confidence of its Board of Directors and management in the company's future and sustainable growth potential. The program may be executed through various methods, allowing flexibility based on market conditions. STAAR has a robust financial position, with $222.8 million in cash and no debt, which supports this initiative. Over the next six months, the company may adjust the program based on ongoing evaluations of its market strategy and financial health.
Read more →STAASTAAR Surgical Reports First Quarter 2025 Results China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast
STAAR Surgical Company reported its first quarter results for 2025, revealing significant challenges in the Chinese market, where net sales fell by 45% year-over-year. Despite these difficulties, sales outside of China increased by 9%, and the company is implementing cost controls and restructuring measures to optimize expenses. CEO Stephen Farrell expressed confidence that EVO ICL procedure trends in China are improving and highlighted ongoing efforts to mitigate tariff impacts. The company also reported a large net loss of $54.2 million, impacted by lower sales and restructuring costs.
Read more →STAASTAAR Surgical Announces Changes to Board of Directors LAKE FOREST, CA –
STAAR Surgical has appointed Louis E. Silverman to its Board of Directors effective April 24, 2025. Silverman previously served on the Board from 2014 to 2022 and is expected to leverage his healthcare leadership experience. Aimee S. Weisner will not seek re-election at the upcoming 2025 annual meeting, and Wei Jiang has taken on a temporary advisory role focusing on the Asia Pacific region. The company is working on improving its cost structure and enhancing profitability amidst evolving global challenges.
Read more →STAASTAAR Surgical Announces Realignment of Leadership Structure Warren Foust Named President and Chief Operating Officer Magda Michna, PhD Appointed Chief Development Officer Deborah Andrews, STAAR's Chief Financial Officer
STAAR Surgical has restructured its leadership team to enhance organizational effectiveness and market responsiveness. Warren Foust has been promoted to President and COO, while Magda Michna takes on the role of Chief Development Officer. Deborah Andrews will serve as Interim CFO following Patrick F. Williams' departure. This realignment aims to drive revenue growth and optimize operations, as stated by CEO Steve Farrell.
Read more →STAASTAAR Surgical Announces Leadership Transition Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair
STAAR Surgical Company has announced a leadership transition with Stephen C. Farrell appointed as the new CEO, succeeding Tom Frinzi, who will continue in an advisory role. Farrell brings significant experience in healthcare and a deep understanding of STAAR's operations from his previous role as Lead Independent Director. Additionally, Elizabeth Yeu, M.D. has been elected as the new Chair of the Board, marking a shift in leadership dynamics. These changes come as the company looks to navigate global economic challenges and capitalize on market growth opportunities in the refractive surgery sector.
Read more →STAASTAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in
STAAR Surgical reported fiscal 2024 results with net sales of $313.9 million and a net loss of $20.2 million, attributed largely to weak macroeconomic conditions in China. While ICL sales excluding China showed growth of 17%, the overall demand downturn significantly affected financial outcomes. The company expects challenges in the first half of fiscal 2025 but anticipates positive growth outside of China moving forward, thanks to investments in the ICL market. An earnings call is scheduled for further discussions regarding the outlook and recent performance.
Read more →STAASTAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on
STAAR Surgical Company announced plans to host a conference call and webcast on February 19, 2025, to discuss its fourth-quarter and fiscal-year financial results. The company reported a year-over-year growth in Implantable Collamer Lens (ICL) sales globally, except in China, where lower consumer confidence remains a concern. The earnings call will provide insights into STAAR's performance and outlook for 2025, especially considering external economic factors. STAAR emphasizes its market leadership through innovative technology in ophthalmic surgery.
Read more →STAASTAAR Surgical Reports Third Quarter 2024 Results Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL Uptake and Reinfor
STAAR Surgical reported a 10% increase in net sales for Q3 2024, reaching $88.6 million, driven by growth across all regions including a 14% increase in the Americas. The company also noted improved net income of $10 million up from $4.8 million the previous year. However, there were challenges such as a decline in gross margin to 77.3% and a significant rise in operating expenses. The company maintains its outlook for 2024, expecting continued growth, particularly from its EVO ICL product line.
Read more →STAASTAAR Surgical Reports Second Quarter 2024 Results Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook
STAAR Surgical reported record net sales of $99.0 million for the second quarter of 2024, representing a 7% increase from the previous year. The company's growth in the Implantable Collamer Lens (ICL) category was driven by strong performances in various geographies, especially a notable 25% rise in U.S. sales. STAAR also raised its fiscal 2024 net sales and adjusted EBITDA outlook, predicting net sales between $340 million and $345 million. However, increased operating expenses were noted, particularly in general and administrative areas, which may affect future profitability.
Read more →STAA▲ +6%on this news
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (
STAAR Surgical's recent investor presentation outlines forward-looking statements regarding financial projections and business strategies for fiscal year 2024 and beyond. The company emphasizes its focus on addressing the global myopia epidemic through its EVO ICL product, which has shown advantages for patients and surgeons. However, it also highlights numerous risks such as economic conditions, regulatory approvals, and market adoption factors that could affect its performance. Investors are advised to monitor updates through the company’s website and SEC filings.
Read more →STAASTAAR Surgical Reports First Quarter 2024 Results EVO ICL Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and
STAAR Surgical reported Q1 2024 results showing a 5% increase in net sales to $77.4 million, driven by a 9% rise in EVO ICL sales. Despite a net loss of $3.3 million, the company maintains strong cash reserves and reaffirms its sales forecast for the fiscal year. Strategic investments appear to be yielding market share growth across various regions, with notable results in the U.S. and China. The company is optimistic about achieving its adjusted EBITDA targets for the year ahead.
Read more →STAA▲ +16.5%on this news· ran to +34% by day 3
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024 Total Net Sales in Excess of $77 Million Including Record Quarterly U.S. ICL Sales of $5 Million
STAAR Surgical Company reported preliminary net sales exceeding $77 million for the first quarter of 2024, highlighted by a record $5 million in U.S. ICL sales since the product's FDA approval in March 2022. The company experienced a 20% sequential increase in U.S. ICL sales and positive growth across EMEA and APAC markets. STAAR forecasts its fiscal 2024 net sales could reach the upper end of its previous guidance of $335 million to $340 million. Full details will be provided during the earnings call on May 8, 2024.
Read more →STAASTAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
STAAR Surgical Company has appointed Arthur Butcher and Wei Jiang to its Board of Directors, effective March 12, 2024. Butcher brings extensive experience from Boston Scientific, while Jiang has over 25 years in the pharmaceutical and medical device industries with Bayer. Their appointments are expected to enhance STAAR’s strategic insights, particularly in the Asia Pacific market, vital for refractive vision correction. Additionally, K. Peony Yu will not seek re-election upon her term's expiration in June 2024, marking a transition in the Board's composition.
Read more →STAAFEBRUARY 26, 2024 / 9:15PM, STAA.OQ - Q4 2023 STAAR Surgical Co Earnings Call FEBRUARY 26, 2024 / 9:15PM, STAA.OQ - Q4 2023 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surg
STAAR Surgical Co. reported strong financial results during its Q4 and fiscal year 2023 earnings call. The company experienced a 22% increase in ICL sales for the fourth quarter and 18% growth for the fiscal year, driven by significant contributions from the APAC and EMEA regions. With a robust cash position of $232 million, STAAR is well-positioned for continued growth, particularly in emerging markets. Additionally, the company's innovative technology shows promise in addressing the growing myopia market, projected to reach $5 billion by 2050.
Read more →STAASTAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results Generates Double-Digit Sales Growth and Continuing Profitability ICL Sales Up 22% in Fourth Quarter and 18% in Fiscal 2023 Affirms Sales Outlook for Fisc
STAAR Surgical Company (NASDAQ: STAA) reported robust financial results for the fourth quarter and fiscal year 2023, highlighted by a 19% increase in net sales and a 22% rise in ICL sales. The company affirmed its strong sales outlook for fiscal year 2024, projecting net sales between $335 million and $340 million. Despite the overall positive growth, STAAR's net income for fiscal year 2023 fell to $21.3 million, down from $39.7 million the previous year, due to rising operating expenses and a significant drop in sales of other products. The company ended the year with a solid cash position of $232 million, offering strategic investment opportunities moving forward.
Read more →STAA▲ +11.5%on this news
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023 Net Sales Up 19% for Fourth Quarter and 13% for Fiscal 2023 1 ICL Sales Up 22% for Fourth Quarter and 18% for Fiscal 2023 Provides Fiscal 20
STAAR Surgical reported preliminary results indicating a 19% increase in net sales for the fourth quarter of fiscal 2023 and a 13% increase for the year, reaching approximately $322.5 million. The company noted a significant surge in global ICL sales, up 22% in the fourth quarter alone. For fiscal 2024, STAAR forecasts net sales of $335 million to $340 million, anticipating continued growth amidst challenging economic conditions. The report highlights a strong operating margin of approximately 5% and ongoing investments in innovation to further enhance market share.
Read more →STAALilian Zhou Appointed to STAAR Surgical Board of Directors
STAAR Surgical Company has appointed Lilian Zhou to its Board of Directors effective December 4, 2023. Zhou, a seasoned investment portfolio manager, has extensive experience in capital markets and previously held leadership positions at various investment firms. Her addition to the Board is anticipated to provide valuable insights into healthcare and ophthalmology, particularly given her background as a former institutional shareholder. Concurrently, Dr. Gil Kliman has stepped down from the Board to focus on other commitments, acknowledging his contributions to STAAR.
Read more →STAAAll statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of
STAAR Surgical's investor presentation outlines forward-looking statements regarding financial projections, strategies, and management objectives for the upcoming years. The company anticipates significant market opportunities driven by the global myopia epidemic, projecting substantial growth in sales due to increasing demand for its EVO intraocular lenses. However, risks associated with regulatory approvals, economic conditions, and market demand uncertainties are acknowledged, which could impact the outcomes of these projections. The company plans to bolster surgeon support and introduce new products to drive market penetration and growth.
Read more →STAA▼ -16.9%on this news
NOVEMBER 01, 2023 / 8:30PM, STAA.OQ - Q3 2023 STAAR Surgical Co Earnings Call Patrick F. Williams - STAAR Surgical Company - CFO Yes. And as a reminder, we actually did not include any material presbyopia or Viva lens in
STAAR Surgical Company recently held its Q3 2023 earnings call where it reported net sales of $80.3 million and a 13% growth in ICL sales. Despite a declining refractive surgery market, STAAR is on track for its sixth consecutive year of double-digit growth and profitability. However, the company expects to meet only the low end of its 2023 sales forecast due to economic challenges in certain regions and possible disruptions in the Middle East. The Indian market is noted as a growing opportunity for future expansion.
Read more →STAASTAAR Surgical Reports Third Quarter 2023 Results Net Sales of $80.3 Million; ICL Sales of $81.1 Million Up 13% Y/Y 23rd Consecutive Quarter of Double-Digit ICL Sales Growth 1
STAAR Surgical Company reported its third quarter 2023 financial results, highlighting net sales of $80.3 million, a 6% increase from the prior year. Sales of their Implantable Collamer Lenses (ICL) rose 13% year-over-year, continuing a trend of double-digit growth for 23 consecutive quarters. However, net income fell to $4.8 million, attributed partially to increased operating expenses. Due to the uncertain economic environment, the company adjusted its fiscal 2023 ICL sales expectations to the lower end of previously forecasted figures.
Read more →STAASTAAR Surgical VISION 2026 STAAR Surgical Investor Day September14,2023 NASDAQ:STAA Agenda Time EDT Topic Speaker 8:30 a.m. Welcome/Safe Harbor Brian Moore, Investor Relations Vision 2026: Achieving STAAR's Global Growth
STAAR Surgical recently hosted its Investor Day focused on its Vision 2026 strategy, which outlines ambitious growth objectives. The company plans to extend its EVO ICL leadership and is targeting significant sales growth across international markets, especially in countries like China and the U.S. Additional discussions included enhancing surgeon support, introducing new products, and addressing the global myopia epidemic. The event concluded with a robust Q&A session aimed at clarifying the company's growth strategies.
Read more →STAAInvestor Presentation STAAR Surgical | NASDAQ: STAA August 2023 Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the f
STAAR Surgical released forward-looking statements during its investor presentation, projecting significant growth opportunities driven by its EVO ICL product. The company reported record sales of $93.1 million for the second quarter of 2023, with a strong sales outlook suggesting potential revenues between $320 million to $325 million for the year. Despite positive market sentiment, risks such as the ongoing COVID-19 pandemic and the necessity of regulatory approvals remain considerable factors influencing future performance. Overall, the company aims to solidify its position in the refractive vision correction market.
Read more →STAAREFINITIV STREETEVENTS EDITED TRANSCRIPT STAA.OQ - Q2 2023 STAAR Surgical Co Earnings Call EVENT DATE/TIME: AUGUST 02, 2023 / 8:30PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us 2023 Refinitiv. All rights
STAAR Surgical Company reported record sales in Q2 2023, largely driven by the success of its EVO family of ICLs, which experienced significant growth, particularly in the APAC market. Despite achieving a total of $93.1 million in ICL sales, the company faced challenges with a 9% sales decline in the EMEA region and a more subdued performance in the U.S. market. As a result, STAAR updated its fiscal 2023 sales outlook to a range of approximately $320 million to $325 million, reflecting ongoing strategic improvements and an adaptive management approach.
Read more →STAASTAAR Surgical Reports Second Quarter 2023 Results Record ICL Sales of $93.1Million Up 19% Y/Y
STAAR Surgical reported impressive financial results for Q2 2023, highlighting record global ICL sales of $93.1 million, up 19% year-over-year, primarily driven by strong demand in the APAC region. While ICL growth in the nascent U.S. market surpassed industry trends, the company updated its fiscal 2023 ICL sales outlook to approximately $320 million to $325 million due to global conservatism. Despite the challenges, STAAR remains optimistic about the market's growth potential and is confident in its strategic initiatives for future expansion.
Read more →STAACompany Name: STAAR Surgical Company (STAA) Event: William Blair 43rd Annual Growth Stock Conference Date
STAAR Surgical Company participated in the William Blair 43rd Annual Growth Stock Conference, where CEO Tom Frinzi highlighted the company's strong growth trajectory and financial performance. The company focuses on its premium implantable contact lens technology to address myopia, boasting a global presence in 75 countries. With only 12% market control, they emphasize vast market opportunities and how they have outperformed competitors in sales growth over the past five years. Additionally, STAAR is enhancing brand awareness through strategic partnerships with influencers and expanding its product offerings.
Read more →STAASTAAR Surgical Reports First Quarter 2023 Results Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y
STAAR Surgical Company reported strong first quarter results for 2023, with a net sales increase of 16% to $73.5 million and ICL sales rising 20% year-over-year to $70.6 million. The company raised its fiscal 2023 net sales outlook to approximately $348 million, reflecting confidence in continued growth driven by robust demand for its EVO ICL lenses. However, net income fell to $2.7 million from $9.6 million in the prior year, attributed to higher operating costs. Despite this, gross margins improved, indicating effective management of production costs.
Read more →STAAMAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Patrick F. W
STAAR Surgical Company reported strong financial results for Q1 2023, highlighting a 20% increase in global ICL sales, which exceeded prior expectations. The company acknowledged ongoing market share gains despite overall refractive surgery procedure volume challenges in various markets. With notable performances in the U.S. and Asia-Pacific, STAAR raised its fiscal 2023 net sales outlook to approximately $348 million, citing targeted marketing efforts and successful surgeon training events as key contributors to this growth.
Read more →STAAMagda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer, STAAR Surgical Company (Photo: Business Wire) 3
STAAR Surgical Company has appointed Warren Foust as Chief Operating Officer and Magda Michna, Ph.D., as Chief Clinical, Regulatory and Medical Affairs Officer. These appointments demonstrate STAAR's focus on enhancing its leadership team to support the growth of its EVO ICL lenses in the refractive vision correction market. Both new leaders have extensive experience in the ophthalmic sector and will work closely with STAAR's President and CEO to drive the company's objectives and establish a new standard of care in the industry.
Read more →STAASTAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results ICL Unit Growth Up 33% Y/Y in Fiscal 2022 STAAR Reaffirms Outlook for Strong Trajectory of Growth in 2023
STAAR Surgical (NASDAQ: STAA) reported strong financial results for the fourth quarter and fiscal year 2022, with a significant year-over-year increase in ICL unit sales. The company's net income for fiscal 2022 rose to $38.8 million, reflecting a growing demand for its implantable lenses. Despite challenges such as increased operating expenses and a decline in other product sales, STAAR remains optimistic, projecting an approximate $340 million in ICL sales for 2023, signaling continued market confidence and investment in growth strategies.
Read more →STAA▲ +9%on this news
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022 ICL Unit Growth of 20% Y/Y for the Fourth Quarter and 33% Y/Y for Fiscal 2022 U.S. ICL Units Up 109% Y/Y for the Fourth Quarter 2022 Outlook for
STAAR Surgical reported preliminary sales, revealing strong growth in ICL units, with a notable 20% increase year-over-year for Q4 and 33% for fiscal 2022. U.S. sales saw an impressive rise of 109% in Q4 alone. The company has updated its fiscal 2023 outlook, projecting approximately $340 million in sales, reflecting a 25% growth from the previous year. STAAR has also been recognized as the fastest growing company in its peer group, indicating significant market momentum.
Read more →STAA▼ -9.5%on this news
STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO Ophthalmic industry executive Tom Frinzi has been appointed President & CEO of STAAR Surgical, effective
STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO LAKE FOREST, CA, December 19, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that President and Chief Executi
Read more →STAASTAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y ICL Units Up 40% Y/Y; Constant Currency Net Sales of $80.0 Million
STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y ICL Units Up 40% Y/Y; Constant Currency Net Sales of $80.0 Million LAKE FOREST, CA, November 2, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable
Read more →STAANOVEMBER 02, 2022 / 8:30PM, STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L
STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call EVENT DATE/TIME: NOVEMBER 02, 2022 / 8:30PM GMT NOVEMBER 02, 2022 / 8:30PM, STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media
Read more →STAA▲ +5.5%on this news· ran to +27% by day 3
AUGUST 10, 2022 / 8:30PM, STAA.OQ - Q2 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L.
AUGUST 10, 2022 / 8:30PM, STAA.OQ - Q2 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director
Read more →STAA▲ +5.5%on this news· ran to +27% by day 3
STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y ICL Units Up 42% Y/Y; Constant Currency Net Sales of $84.2 Million Announces Partnership with Joe Jonas to Raise EVO Global Awareness
STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y ICL Units Up 42% Y/Y; Constant Currency Net Sales of $84.2 Million Announces Partnership with Joe Jonas to Raise EVO Global Awareness LAKE FOREST, CA, August 10, 2022 --- STAAR Surgical Company
Read more →STAAMAY 04, 2022 / 8:30PM, STAA.OQ - Q1 2022 STAAR Surgical Co Earnings Call D I S C L A I M E R Refinitiv reserves the right to make changes to documents, content, or other information on this web site without obligation to
MAY 04, 2022 / 8:30PM, STAA.OQ - Q1 2022 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director Pa
Read more →STAA▲ +5.2%on this newsshared move
STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y EVO Visian ICL Lenses Received FDA Approval and First Lenses Implanted
STAAR Surgical Reports Record First Quarter Net Sales of $63.2 Million Up 25% Y/Y EVO Visian ICL Lenses Received FDA Approval and First Lenses Implanted LAKE FOREST, CA, May 4, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of imp
Read more →STAASTAAR Surgical Announces First Implants of EVO Visian ICL in the U.S. Announces Program of Meetings and Presentations at Upcoming ASCRS Annual Meeting
STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S. Announces Program of Meetings and Presentations at Upcoming ASCRS Annual Meeting LAKE FOREST, CA, April 6, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of imp
Read more →STAA▲ +10.6%on this news
STAAR Surgical Announces U.S. FDA Approval of EVO Visian Implantable Collamer Lenses EVO Lenses Provide Visual Freedom from Contact Lenses and Glasses Over One Million EVO Lenses Have Already Been Implanted Worldwide Inf
STAAR Surgical Announces U.S. FDA Approval of EVO Visian Implantable Collamer Lenses EVO Lenses Provide Visual Freedom from Contact Lenses and Glasses Over One Million EVO Lenses Have Already Been Implanted Worldwide Information for Patients and Doctor Finder at DiscoverEVO.co
Read more →STAA▲ +18.4%on this news· ran to +28% by day 3
FEBRUARY 23, 2022 / 9:30PM, STAA.OQ - Q4 2021 STAAR Surgical Co Earnings Call Caren L. Mason - STAAR Surgical Company - CEO, President & Director Thank you very much. Operator That concludes our Q&A session. So, I would
STAA.OQ - Q4 2021 STAAR Surgical Co Earnings Call EVENT DATE/TIME: FEBRUARY 23, 2022 / 9:30PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us FEBRUARY 23, 2022 / 9:30PM, STAA.OQ - Q4 2021 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S B
Read more →STAASTAAR Surgical Reports Fourth Quarter and Full Year 2021 Results
STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results LAKE FOREST, CA, February 23, 2022 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financia
Read more →STAASTAAR Surgical Investor Presentation NASDAQ: STAA | February 2022 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial p
STAAR Surgical Investor Presentation NASDAQ: STAA | February 2022 All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objec
Read more →STAASTAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results Achieves 40% Growth Y/Y with Full Year 2021 Net Sales of Approximately $230 Million Fourth Quarter Net Sales Approximately $59 Million
STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results Achieves 40% Growth Y/Y with Full Year 2021 Net Sales of Approximately $230 Million Fourth Quarter Net Sales Approximately $59 Million LAKE FOREST, CA, January 10, 2022--- STAAR Surgical Company (NA
Read more →STAAREFINITIV STREETEVENTS | www.refinitiv.com | Contact Us 2021 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior wr
NOVEMBER 03, 2021 / 8:30PM, STAA.OQ - Q3 2021 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Directo
Read more →STAASTAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y Third Quarter ICL Sales Up 31% Y/Y and Units Up 29% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $230 Million to $231 Million
STAAR Surgical Reports Third Quarter Net Sales of $58.4 Million Up 24% Y/Y Third Quarter ICL Sales Up 31% Y/Y and Units Up 29% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $230 Million to $231 Million LAKE FOREST, CA, November 3, 2021 --- STAAR Surgical Company (
Read more →STAA▼ -6.1%on this news
Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, st
STAAR Surgical Company Investor presentation August 2021 Exhibit 99.1 Forward Looking Statements All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales
Read more →STAA▲ +20.4%on this newsshared move
AUGUST 04, 2021 / 8:30PM, STAA.OQ - Q2 2021 STAAR Surgical Co Earnings Call Caren L. Mason - STAAR Surgical Company - CEO, President & Director Yes. We have extensive options and opportunities that surgeons can work with
AUGUST 04, 2021 / 8:30PM, STAA.OQ - Q2 2021 STAAR Surgical Co Earnings Call C O R P O R A T E P A R T I C I P A N T S Brian Moore STAAR Surgical Company - VP of Investor, Media Relations & Corporate Development Caren L. Mason STAAR Surgical Company - CEO, President & Director
Read more →STAASTAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021 Second Quarter ICL Sales Up 93% Y/Y and Units Up 79% Y/Y Increases Full Year 2021 Net Sales Outlook to Ran
STAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021 Second Quarter ICL Sales Up 93% Y/Y and Units Up 79% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $227 Million to $230 Million LAKE FOREST, CA, Augus
Read more →STAAkick in the gear here. And then the follow up would be specifically on the US and EU implant numbers, obviously much higher than what we expected. Are you seeing any buy-in of the legacy products ahead of a full scale of
STAAR Surgical Q1 2021 Earnings Call Transcript CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Williams, Chief Financial Officer, STAAR Surgical Brian Moore, Vice President-Investor, Media Relations and Corporate D
Read more →STAASTAAR Surgical Reports Record First Quarter 2021 Net Sales of $50.8 Million Up 44% Y/Y First Quarter ICL Sales Up 58% Y/Y and Units Up 54% Y/Y Announces Submission of Clinical Trial Data to U.S. FDA for EVO Family of Myo
STAAR Surgical Reports Record First Quarter 2021 Net Sales of $50.8 Million Up 44% Y/Y First Quarter ICL Sales Up 58% Y/Y and Units Up 54% Y/Y Announces Submission of Clinical Trial Data to U.S. FDA for EVO Family of Myopia Lenses Introduces Net Sales Outlook of Approximately
Read more →STAAThank you, operator, and thanks, everyone, for your participation on our call today. We look forward to speaking with many of you in the days and weeks ahead. We appreciate your interest and investment in STAAR surgical.
STAAR Surgical Q4 2020 Earnings Call Transcript Date: February 24, 2021 CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Williams, Chief Financial Officer, STAAR Surgical Brian Moore, Vice President-Investor, Media
Read more →STAAConsolidated Statements of Cash Flows (in 000's) Unaudited Three Months Ended Twelve Months Ended
STAAR Surgical Reports Fourth Quarter and Full Year 2020 Results LAKE FOREST, CA, February 24, 2021 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financia
Read more →STAAElizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors
Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors LAKE FOREST, CA, January 26, 2021 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye,
Read more →STAASTAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2020 Results Net Sales Approximately $46 Million in Fourth Quarter and $163 Million for Full Year
STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2020 Results Net Sales Approximately $46 Million in Fourth Quarter and $163 Million for Full Year LAKE FOREST, CA, January 10, 2021--- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and
Read more →STAASure. Just as a reminder Bruce, last year, we switched from our normal sequential growth quarter-by-quarter through Q4, and Q3 became our largest quarter. And it is really based now on China being a big part of our units
STAAR Surgical Q3 2020 Earnings Call Transcript Date: November 4, 2020 CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Williams, Chief Financial Officer, STAAR Surgical Brian Moore, Vice President-Investor, Media R
Read more →STAASTAAR Surgical Reports Third Quarter 2020 Results
STAAR Surgical Reports Third Quarter 2020 Results LAKE FOREST, CA, November 4, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for th
Read more →STAASTAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial Pivotal Study Successfully Enrolls 300 Subjects Across 14 U.S. Sites
STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial Pivotal Study Successfully Enrolls 300 Subjects Across 14 U.S. Sites LAKE FOREST, CA, September 14, 2020--- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufactur
Read more →STAAForward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, plans,
STAAR Surgical Company Investor presentation September 2020 Exhibit 99.1 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial proje
Read more →STAASo, thank you for your participation on our call today. We look forward to speaking with many of you in the days and weeks ahead. We appreciate your interest and investment in STAAR Surgical. Please take good care. All t
STAAR Surgical Q2 2020 Earnings Call Transcript Date: August 5, 2020 CORPORATE PARTICIPANTS Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Patrick F. Wi
Read more →STAASTAAR Surgical Reports Second Quarter 2020 Results
STAAR Surgical Reports Second Quarter 2020 Results LAKE FOREST, CA, August 5, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
Read more →STAASTAAR Surgical Introduces EVO Viva Presbyopia Correcting Lens - See Young Again! Receives CE Mark Approval from European Notified Body EVO Viva Implantable Collamer Lens Corrects Near, Intermediate and Distance Vision
STAAR Surgical Introduces EVO Viva Presbyopia Correcting Lens - See Young Again! Receives CE Mark Approval from European Notified Body EVO Viva Implantable Collamer Lens Corrects Near, Intermediate and Distance Vision LAKE FOREST, CA, July 7, 2020 --- STAAR Surgical Company (N
Read more →STAAPatrick F. Williams Appointed Chief Financial Officer of STAAR Surgical Deborah Andrews to Remain in Advisory Role During Transition
Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical Deborah Andrews to Remain in Advisory Role During Transition LAKE FOREST, CA, July 6, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and
Read more →STAADr. Gil Kliman and Tom Frinzi Appointed to STAAR Surgical Board of Directors
Dr. Gil Kliman and Tom Frinzi Appointed to STAAR Surgical Board of Directors LAKE FOREST, CA, June 1, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced
Read more →STAAproductivity. And we know we will have the inventory necessary for demand as we see it going forward beyond double digits, so we're in good shape. James Sidoti, Analyst, Sidoti & Co. Okay. Thank you. Caren Mason, Preside
STAAR Surgical Q1 2020 Earnings Call Transcript Thank you for standing by, and welcome to the STAAR Surgical 1Q 2020 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there'll be a question-
Read more →STAASTAAR Surgical Reports First Quarter 2020 Results
STAAR Surgical Reports First Quarter 2020 Results LAKE FOREST, CA, May 6, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fir
Read more →STAASTAAR Surgical Provides COVID-19 Business Update
STAAR Surgical Provides COVID-19 Business Update LAKE FOREST, CA, April 13, 2020 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided a business update relating
Read more →STAACaren Mason, President, Chief Executive Officer & Director, STAAR Surgical The EDOF toric pilot study at this point in time will -is scheduled definitely in 2020. We have not finalized the date, but we have everything re
STAAR Surgical Q4 2019 Earnings Call Transcript Date: February 26, 2020 CORPORATE PARTICIPANTS Caren Mason, President, Chief Executive Officer & Director, STAAR Surgical Deborah J. Andrews, Chief Financial Officer, STAAR Surgical Brian Moore, Senior Director-Investor, Media
Read more →STAASTAAR Surgical Reports Fourth Quarter and Full Year 2019 Results
STAAR Surgical Reports Fourth Quarter and Full Year 2019 Results LAKE FOREST, CA, February 26, 2020--- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial
Read more →STAASTAAR Surgical Announces the EVO Implantable Lens US Clinical Trial is Underway with 1st Patient Implanted at Price Vision Group in Indianapolis on January 30th LAKE FOREST, CA, and INDIANAPOLIS, IN
STAAR Surgical Announces the EVO Implantable Lens US Clinical Trial is Underway with 1st Patient Implanted at Price Vision Group in Indianapolis on January 30th LAKE FOREST, CA, and INDIANAPOLIS, IN, February 4, 2020--- STAAR Surgical Company (NASDAQ: STAA), a leading developer,
Read more →STAASTAAR Surgical Reports Preliminary Fourth Quarter Net Sales Growth of 25% Achieves 33% ICL Unit Growth for Fiscal 2019 Provides Initial Outlook for Fiscal 2020
STAAR Surgical Reports Preliminary Fourth Quarter Net Sales Growth of 25% Achieves 33% ICL Unit Growth for Fiscal 2019 Provides Initial Outlook for Fiscal 2020 LAKE FOREST, CA, January 13, 2020--- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and mar
Read more →STAASTAAR CFO to Retire in 2020 Deborah Andrews Plans to Retire After 24 Years with the Company
STAAR CFO to Retire in 2020 Deborah Andrews Plans to Retire After 24 Years with the Company LAKE FOREST, CA, December 18, 2019 -- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the ey
Read more →STAASTAAR Surgical Announces FDA IDE Clinical Study Approval EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN Toric Implantable Collamer Lens for Myopia with Astigmatism
STAAR Surgical Announces FDA IDE Clinical Study Approval EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN Toric Implantable Collamer Lens for Myopia with Astigmatism LAKE FOREST, CA, December 11, 2019--- STAAR Surgical Company (NASDAQ: STAA), a leading
Read more →STAAForward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about the Ophthalmic industry, our business and financial res
STAAR Surgical Caren Mason President & CEO 2019 Investor Day Presentation | NASDAQ: STAA November 8, 2019 Exhibit 99.1 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements a
Read more →STAASTAAR Surgical Reports Third Quarter Results
STAAR Surgical Reports Third Quarter Results LAKE FOREST, CA, October 30, 2019--- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the thir
Read more →STAArelease, see STAAR's Annual Report on Form 10-K for the year ended
STAAR Surgical Announces FDA IDE Clinical Study Approval EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN Toric Implantable Collamer Lens for Myopia with Astigmatism Additional Study Recommendations and Considerations to be Addressed LAKE FOREST, CA,
Read more →STAAForward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, includ
STAAR Surgical NASDAQ: STAA www.staar.com / www.discoverevo.com Investor Presentation | August 7, 2019 Exhibit 99.1 Exhibit 99.1 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including st
Read more →STAAYes. I mean, if you look at the calendarization of sales last year, you are going to see similar trends in the calendarization this year. Just look at the percentage of contribution of each of the quarters that will tell
Company Participants Caren Mason - President and Chief Executive Officer Deborah Andrews - Chief Financial Officer Brian Moore - Sr. Director, Media, Investor Relations and Corporate Development Conference Call Participants Chris Cooley - Stephens Jason Mills, Cecilia Furlo
Read more →STAASTAAR Surgical Company Reconciliation of Non-GAAP Financial Measure Constant Currency Sales (in 000's) Unaudited Three Months Ended
STAAR Surgical Reports Record Second Quarter Results for Total Revenue, ICL Sales and ICL Units LAKE FOREST, CA, July 31, 2019--- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the e
Read more →STAAstaa-ex991_16.pptx.htm STAAR Surgical NASDAQ: STAA www.staar.com / www.discoverevo.com Investor Presentation |
STAAR Surgical NASDAQ: STAA www.staar.com / www.discoverevo.com Investor Presentation | June 5, 2019 99.1 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward-looking statements, including statements about any of t
Read more →STAAwelcoming a UBS investor bus tour at our Lake Forest headquarters on May 16th. And we look forward to seeing many of you at the Jeffries Healthcare Conference in New York on June 5th. As always, we appreciate your intere
PRESENTATIONOperatorGood day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical First Quarter 2019 Financial Results Conference Call. (Operator Instructions) This call is also being recorded today, Wednesday, May 1, 2019. At this time, I'd like to tur
Read more →STAAReconciliation of Non-GAAP Financial Measure (in 000's) Unaudited Three Months Ended
STAAR Surgical Reports First Quarter Results ICL Units Up 39% Resulting in Seventh Consecutive Quarter of Significant Growth Earnings per Share of $0.03 Announces U.S. Surgeons Summit LAKE FOREST, CA, May 1, 2019--- STAAR Surgical Company (NASDAQ: STAA), a leading developer,
Read more →STAASTAAR Surgical Company NASDAQ: STAA Investor Presentation |
STAAR Surgical Company NASDAQ: STAA Investor Presentation | February 28, 2019 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any financia
Read more →STAAPRESENTATION Operator Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical Fourth Quarter and Full Year 2018 Financial Results Conference Call. (Operator Instructions) This call is bei
Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical Fourth Quarter and Full Year 2018 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Thursday, February 21, 2019. At this time, I would like to t
Read more →STAASTAAR Surgical Reports Fourth Quarter and Full Year 2018 Results Fourth Quarter ICL Sales Rise 41%; Full Year 2018 ICL Sales Rise 48% GAAP Net Income of $0.02 Per Share in Fourth Quarter; $0.11 Per Share for Full Year 20
STAAR Surgical Reports Fourth Quarter and Full Year 2018 Results Fourth Quarter ICL Sales Rise 41%; Full Year 2018 ICL Sales Rise 48% GAAP Net Income of $0.02 Per Share in Fourth Quarter; $0.11 Per Share for Full Year 2018 MONROVIA, CA, February 21, 2019--- STAAR Surgical
Read more →STAASTAAR Surgical Company NASDAQ: STAA Investor Presentation | January 17, 2019
STAAR Surgical Company NASDAQ: STAA Investor Presentation | January 17, 2019 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any financial
Read more →STAASTAAR Surgical Expects Fourth Quarter ICL Sales to Rise 42%; China Units Nearly Double, U.S. Market Returns to Growth MONROVIA, CA
STAAR Surgical Expects Fourth Quarter ICL Sales to Rise 42%; China Units Nearly Double, U.S. Market Returns to Growth MONROVIA, CA, January 7, 2019---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion deliv
Read more →STAASTAAR Surgical Company NASDAQ: STAA Investor Presentation | November 2018
STAAR Surgical Company NASDAQ: STAA Investor Presentation | November 2018 Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any financial pr
Read more →STAAPRESENTATION Operator Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical Third Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being recorded tod
Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical Third Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, October 31, 2018. At this time, I would like to turn the confere
Read more →STAASTAAR Surgical ICL Sales Up 46%; Company Raises Outlook for Full Year 2018 MONROVIA, CA
STAAR Surgical ICL Sales Up 46%; Company Raises Outlook for Full Year MONROVIA, CA, October 31, 2018---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financi
Read more →STAASTAAR Surgical Announces Approval by the FDA of the Visian Toric ICL for the Correction of Myopia with Astigmatism MONROVIA, CA
STAAR Surgical Announces Approval of the Visian Toric ICL for the Correction of Myopia with Astigmatism MONROVIA, CA, September 13, 2018---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery system
Read more →STAASTAAR Surgical Company NASDAQ: STAA
STAAR Surgical Company NASDAQ: STAA August 22, 2018 Forward Looking Statements ; All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any financial projections, including
Read more →STAASTAAR Surgical Company Canaccord Growth Conference NASDAQ: STAA
STAAR Surgical Company Canaccord Growth Conference NASDAQ: STAA August 8, 2018 Forward Looking Statements ; All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any finan
Read more →STAAOperator Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical Second Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesda
Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical Second Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, August 1, 2018. At this time, I would like to turn the conferen
Read more →STAASTAAR Surgical ICL Sales Up 67%; Company Raises Outlook for 2018 MONROVIA, CA
STAAR Surgical ICL Sales Up 67%; Company Raises Outlook for 2018 MONROVIA, CA, August 1, 2018---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial resu
Read more →STAASTAAR Surgical Announces Resolution of FDA Warning Letter MONROVIA, CA
STAAR Surgical Announces Resolution of MONROVIA, CA, June 20, 2018---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye announced today that it received a close-out letter from
Read more →STAAMAY 02, 2018 / 4:30PM EDT, Q1 2018 STAAR Surgical Co Earnings Call PRESENTATION Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical First Quarter 2018 Financial Results Confe
Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical First Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, May 2, 2018. At this time, I would like to turn the conference o
Read more →STAASTAAR Surgical Reports First Quarter 2018 Results; Revenue Increases 33 Percent on Accelerating EVO Visian ICL Momentum MONROVIA, CA
STAAR Surgical Reports First Quarter 2018 Results; Revenue Increases 33 Percent EVO Visian ICL Momentum MONROVIA, CA, May 2, 2018---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for
Read more →STAASTAAR Surgical Company Investor Presentation NASDAQ: STAA March 2018 Evolution in Visual Freedom Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward - loo
STAAR Surgical Company Investor Presentation NASDAQ: STAA March 2018 Evolution in Visual Freedom Forward Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the foll
Read more →STAAOperator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Fourth Quarter and Full Year 2017 Financial Results Conference Call. (Operator Instructions) This call is being recorded t
day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Fourth Quarter and Full Year 2017 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, February 28, 2018. this time, I would like to turn the
Read more →STAASTAAR Surgical Reports Fourth Quarter and Full Year 2017 Results MONROVIA, CA
Reports Fourth Quarter and Full Year 2017 Results MONROVIA, CA, February 28, 2018---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the f
Read more →STAAA Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction Investor Update NASDAQ : STAA
A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction Investor Update NASDAQ : STAA January 8, 2018 Evolution in Visual Freedom 1 BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in
Read more →STAAA Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction Investor and Analyst Day NASDAQ: STAA
A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction Investor and Analyst Day NASDAQ: STAA November 16, 2017 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All state
Read more →STAAOperator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Third Quarter 2017 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday
day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Third Quarter 2017 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, November 8, 2017. At this time, I would like to turn the conference ov
Read more →STAASTAAR Surgical Reports Third Quarter 2017 Results MONROVIA, CA
STAAR Surgical Reports Third Quarter 2017 Results MONROVIA, CA, November 8, 2017---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the th
Read more →STAASTAAR Surgical Appoints Scott D. Barnes, M.D. as Chief Medical Officer Distinguished Ophthalmology Clinician to Serve as Strategic Guide for STAAR's Medical & Professional Affairs as well as Product Development Pathways
STAAR Surgical Appoints Scott D. Barnes, M.D. as Chief Medical Officer Ophthalmology Clinician to Serve as Strategic Guide for STAAR's Medical & Professional Affairs as well as Product Development MONROVIA, CA, October 2, 2017---STAAR Surgical Company (NASDAQ: STAA) a leadin
Read more →STAASTAAR Surgical Names Deborah Andrews as CFO Surindra Mann Joins STAAR as Vice President, Global Financial Planning & Analysis MONROVIA, CA
STAAR Surgical Names Deborah Andrews Surindra Mann Joins STAAR as Vice President, Global Financial Planning & Analysis MONROVIA, CA, September 28, 2017-STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion del
Read more →STAAINVESTOR PRESENTATION NASDAQ: STAA September 2017 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements of his
INVESTOR PRESENTATION NASDAQ: STAA September 2017 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements of historical fact are forward - looking statements, including st
Read more →STAASTAAR Surgical and Seoul/Busan BalGeunSeSang Eye Clinic Announce Strategic Cooperation Agreement MONROVIA, CA
STAAR Surgical and Seoul/Busan BalGeunSeSang Eye Clinic Announce Strategic Cooperation Agreement August 15, 2017---STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, and Dr. Jong Ho Lee,
Read more →STAAINVESTOR PRESENTATION NASDAQ: STAA August 2017 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements of histor
INVESTOR PRESENTATION NASDAQ: STAA August 2017 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements of historical fact are forward - looking statements, including state
Read more →STAAOperator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Second Quarter 2017 Financial Results Conference Call. (Operator Instructions). This call is being recorded today, Wednesd
day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Second Quarter 2017 Financial Results Conference Call. (Operator Instructions). This call is being recorded today, Wednesday, August 2, 2017. At this time, I would like to turn the conference ov
Read more →STAASTAAR Surgical Reports Second Quarter 2017 Results MONROVIA, CA
STAAR Surgical Reports Second Quarter 2017 MONROVIA, CA, August 2, 2017---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the second quar
Read more →STAASTAAR Surgical Announces CE Mark Approval for the EVO+ Visian ICL with Aspheric (EDOF) Optic MONROVIA, CA
STAAR Surgical Announces CE Mark Approval for the EVO+ Visian ICL with Aspheric (EDOF) Optic May 11, 2017--- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, has received CE
Read more →STAAOperator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical First Quarter 2017 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday
day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical First Quarter 2017 Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, May 3, 2017. At this time, I'd like to turn the conference over to Mr.
Read more →STAASTAAR Surgical Reports First Quarter 2017 Results MONROVIA, CA
STAAR Surgical Reports First Quarter 2017 MONROVIA, CA, May 3, 2017---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the first quarter e
Read more →STAASTAAR Surgical Names Deborah Andrews Interim CFO Steve Brown Resignation Effective
STAAR Surgical Names Deborah Andrews Steve Brown Resignation Effective April MONROVIA, CA, April 5, 2017---STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced today th
Read more →STAABrian Moore - STAAR Surgical Company - EVC Group - IR Thank you Vince, good afternoon everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to review the Company's financial results for
Surgical Company - EVC Group - IR you Vince, good afternoon everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to review the Company's financial results for the fourth quarter which ended on December 30, 2016. On the call today are Caren Mas
Read more →STAASTAAR Surgical Reports Fourth Quarter
STAAR Surgical Reports Fourth Quarter MONROVIA, CA, March 2, 2017-STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the fourth quarter ende
Read more →STAAINVESTOR PRESENTATION JANUARY 10 & 11, 2017 Evolution in Visual Freedom STAA: NASDAQ BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements
INVESTOR PRESENTATION JANUARY 10 & 11, 2017 Evolution in Visual Freedom STAA: NASDAQ BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements of historical fact are forward - looking statements, inclu
Read more →STAAEDITED TRANSCRIPT STAA - Q3 2016 STAAR Surgical Co Earnings Call EVENT DATE/TIME: NOVEMBER 03, 2016 / 04:30PM ET 1 NOVEMBER 03, 2016 / 04:30PM ET, STAA - Q3 2016 STAAR Surgical Co Earnings Call CORPORATE PARTICIPANTS Bri
EDITED TRANSCRIPT STAA - Q3 2016 STAAR Surgical Co Earnings Call EVENT DATE/TIME: NOVEMBER 03, 2016 / 04:30PM ET CORPORATE PARTICIPANTS Surgical Company - President, CEO Surgical Company - VP, CFO Benchmark Company - Analyst day, ladies and gentlemen. Thank you for standing
Read more →STAASTAAR Surgical Reports Third Quarter
STAAR Surgical Reports Third Quarter MONROVIA, CA, November 3, 2016-STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the third quarter end
Read more →STAASTAAR Surgical Announces Approval by Health Canada of Its EVO Visian ICL Toric Lens Specifically Designed for the Nearsighted Patient with Astigmatism Expanded Line of Evolution in Visual Freedom Lenses Now Available in
STAAR Surgical Announces Approval by Health Canada of Its EVO Visian ICL Toric Lens Specifically Designed for the Nearsighted Patient with Astigmatism Expanded Line of Evolution in Visual Freedom Lenses Now Available in Canada MONROVIA, CA, September 22, 2016---STAAR Surgi
Read more →STAALeading Refractive Surgery Provider, EyeQ Vision Private Ltd., Gurgaon, India and STAAR Surgical Announce Strategic Cooperation Agreement Forty Four Hospitals with Seventy Surgeons Commit to Establishing the EVO Visian I
Surgery Provider, EyeQ Vision Private Ltd., Announce Strategic Cooperation Forty Four Hospitals with Seventy Surgeons Commit to Establishing the EVO Visian Implantable Collamer Lens as a Premium and Primary Refractive Procedure CA, September 15, 2016---STAAR Surgical Company
Read more →STAASTAAR Surgical Announces Strategic Cooperation Agreement With World Eye Hospital Group With 30,000 Refractive Procedures Performed Annually in 21 Clinics, World Eye Hospital Group is the Largest Provider in Southeast Eur
STAAR Surgical Announces Strategic Cooperation Agreement With World Eye Hospital Group With 30,000 Refractive Procedures Performed Annually in 21 Clinics, Hospital Group is the Largest Provider in Southeast Europe MONROVIA, CA, September 7, 2016---STAAR Surgical Company (N
Read more →STAAC ANACCORD G ROWTH C ONFERENCE A UGUST 10, 2016 Evolution in Visual Freedom 1 BUILDING A FOUNDATION FOR CONSISTENT GROWTH FORWARD - LOOKING STATEMENTS All statements in this presentation that are not statements of histor
C ANACCORD G ROWTH C ONFERENCE A UGUST 10, 2016 Evolution in Visual Freedom 1 BUILDING A FOUNDATION FOR CONSISTENT GROWTH FORWARD - LOOKING STATEMENTS All statements in this presentation that are not statements of historical fact are forward - looking statements, including state
Read more →STAATRANSCRIPT STAA - Q2 2016 STAAR Surgical Co Earnings Call EVENT DATE/TIME: AUGUST 03, 2016 / 04:30PM ET 1 CORPORATE PARTICIPANTS Brian Moore EVC Group - IR Caren Mason STAAR Surgical Company - President, CEO Steve Brown
TRANSCRIPT STAA - Q2 2016 STAAR Surgical Co Earnings Call EVENT DATE/TIME: AUGUST 03, 2016 / 04:30PM ET CORPORATE PARTICIPANTS Moore EVC Group - IR Mason STAAR Surgical Company - President, CEO Brown STAAR Surgical Company - CFO Myers Benchmark Capital - Analyst Sidoti Sido
Read more →STAASTAAR Surgical Reports Second Quarter 2016 Results MONROVIA, CA
Surgical Reports Second Quarter 2016 Results MONROVIA, CA, August 3, 2016---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the second qu
Read more →STAAJ EFFERIES H EALTHCARE CONFERENCE J UNE 10, 2016 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH FORWARD - LOOKING STATEMENTS All statements in this presentation that are not statements of histori
J EFFERIES H EALTHCARE CONFERENCE J UNE 10, 2016 Evolution in Visual Freedom BUILDING A FOUNDATION FOR CONSISTENT GROWTH FORWARD - LOOKING STATEMENTS All statements in this presentation that are not statements of historical fact are forward - looking statements, including statem
Read more →STAASTAAR Surgical Announces Approval By Health Canada of Its EVO Visian ICL for Surgeons and Their Patients in Canada MONROVIA, CA
STAAR Surgical Announces Approval By Health Canada of Its EVO Visian ICL for Surgeons and Their Patients in Canada MONROVIA, CA, May 13, 2016---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery sy
Read more →STAATranscript of STAA earnings conference call
Transcript of STAA earnings conference * Brian Moore, EVC Group - IR * Caren Mason, STAAR Surgical Co - * Steve Brown, STAAR Surgical Co - Conference Call Participants * Chris Cooley, Stephens Inc. - Analyst * Matt Larew, William Blair & Company * Jeff Chu, Canaccord Genui
Read more →STAASTAAR Surgical Reports First Quarter 2016 Results MONROVIA, CA
STAAR Surgical Reports First Quarter MONROVIA, CA, May 11, 2016---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported financial results for the first quarter ended April 1,
Read more →STAAEdited Transcript of STAA earnings conference call or presentation 2-Mar-16 4:30pm ET Corporate Participants * Brian Moore EVC Group - IR * Caren Mason STAAR Surgical Co - President & CEO * Steve Brown STAAR Surgical Co
Edited Transcript of STAA earnings conference call or presentation Corporate Participants STAAR Surgical Co - President & CEO STAAR Surgical Co - CFO Conference Call Participants Stephens Inc. - Analyst Benchmark Capital - Analyst William Blair & Company - Analyst Sidoti
Read more →STAASTAAR Surgical Reports Fourth Quarter and Full Year 2015 Results MONROVIA, CA
STAAR Surgical Reports Fourth Quarter and Full Year 2015 Results MONROVIA, CA, March 2, 2016---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported financial results for the
Read more →STAASTAAR Surgical and Aier Eye Hospital Group Announce Strategic Cooperation Agreement Agreement Addresses Significant Need for Refractive Surgery in Chinese Population with Mid to High Myopic Correction Requirements MONROV
STAAR Surgical and Aier Eye Hospital Group Announce Strategic Cooperation Agreement Agreement Addresses Significant Need for Refractive Surgery in Chinese Population with Mid to High Myopic Correction Requirements MONROVIA, CA, February 16, 2016---STAAR Surgical Company (NAS
Read more →STAASTAAR Surgical Company and Memira Holding Announce Cooperation Agreement for Memira's Eye Clinics throughout Scandinavia MONROVIA, CA
STAAR Surgical Company and Memira Holding Announce Cooperation Agreement for Memira's Eye Clinics throughout Scandinavia MONROVIA, CA, February 9, 2016---STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery sys
Read more →STAAInvestor Update January 11 & 12, 2016 1 NASDAQ : STAA All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any
Investor Update January 11 & 12, 2016 1 NASDAQ : STAA All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any projections of earnings, revenue, sales, profit margins, ca
Read more →STAAStephen C. Farrell Appointed to STAAR Surgical Board of Directors Company Also Reports Adoption of Governance Changes MONROVIA, CA
Stephen C. Farrell Appointed to STAAR Surgical Board of Directors Company Also Reports Adoption of Governance MONROVIA, CA, December 17, 2015--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for
Read more →STAAEvent Name: Q3 2015 STAAR Surgical Co Earnings Call Event Date: 2015-10-28 / 4:30 pm ET +++ presentation Operator^ Good day, ladies and gentlemen. Thank you for standing by. Welcome to STAAR Surgical's Third Quarter 2015
Event Name: Q3 2015 STAAR Surgical Co Earnings Call Event Date: 2015-10-28 / 4:30 pm ET Operator^ Good day, ladies and gentlemen. Thank you for standing by. Welcome to STAAR Surgical's Third Quarter 2015 Financial Results Conference Call. (Operator Instructions) This call is b
Read more →STAASTAAR Surgical Reports Third Quarter 2015 Results MONROVIA, CA
STAAR Surgical Reports Third Quarter MONROVIA, CA, October 28, 2015---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported financial results for the third quarter ended Octob
Read more →STAAWilliam P. Wall Appointed to STAAR Surgical Board of Directors MONROVIA, CA
William P. Wall Appointed to STAAR Surgical MONROVIA, CA, September 2, 2015--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that its Board of Directors has appointed
Read more →STAADr. Keith Holliday Named Vice President Research and Development for STAAR Surgical MONROVIA, CA
Dr. Keith Holliday Named Vice President Research and Development for STAAR Surgical MONROVIA, CA, August 6, 2015--STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, has named Keith Holli
Read more →STAASTAAR Surgical Reports Second Quarter 2015 Results MONROVIA, CA
STAAR Surgical Reports Second Quarter MONROVIA, CA, July 29, 2015---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported financial results for the second quarter ended July 3
Read more →STAADr. Jon K. Hayashida Named Vice President Global Clinical and Medical Affairs for STAAR Surgical MONROVIA, CA
Dr. Jon K. Hayashida Named Vice Global Clinical and Medical Affairs for MONROVIA, CA, July 23, 2015---STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, has named Dr. Jon K. Hayashida to
Read more →STAACORPORATE PARTICIPANTS Brian Moore - EVC Group - IR Caren Mason STAAR Surgical - President & CEO Steve Brown STAAR Surgical - CFO CONFERENCE CALL PARTICIPANTS Chris Cooley Stephens, Inc. - Analyst James Sidoti Sidoti & C
CORPORATE PARTICIPANTS Brian Moore - EVC Group - IR Caren Mason STAAR Surgical - President & CEO Steve Brown STAAR Surgical - CFO CONFERENCE CALL PARTICIPANTS Chris Cooley Stephens, Inc. - Analyst James Sidoti Sidoti & Company - Analyst Matt Larew William Blair & Company,
Read more →STAANASDAQ: STAA May 7 th 1 All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any projections of earnings, reven
NASDAQ: STAA May 7 th 1 All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any projections of earnings, revenue, sales, profit margins, cash, effective tax rate or any
Read more →STAASTAAR Surgical Reports First Quarter 2015 Results MONROVIA, CA
STAAR Surgical Reports First Quarter MONROVIA, CA, April 29, 2015---STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today reported financial results for the first quarter ended April
Read more →STAAJ. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors MONROVIA, CA
J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors MONROVIA, CA, April 21, 2015 -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that its Board of
Read more →STAATHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT STAA - Q4 2014 STAAR Surgical Co Earnings Call EVENT DATE/TIME: FEBRUARY 25, 2015 / 4:30PM ET THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2015 Thomson R
STREETEVENTS | www.streetevents.com | Contact Us C O R P O R A T E P A R T I C I P A N T S Doug Sherk STAAR Surgical Company - EVC Group Barry Caldwell STAAR Surgical Company - President Steve Brown STAAR Surgical Company - CFO Sam Gesten STAAR Surgical Company - General Cou
Read more →STAACaren Mason Appointed President & CEO of STAAR Surgical Company Accomplished Leader Brings Broad Expertise and Proven Track Record of Building Successful Healthcare Companies Elected to STAAR's Board of Directors in June
Caren Mason Appointed President & CEO of STAAR Surgical Company Brings Broad Expertise and Proven Track Record of Building Successful Healthcare Companies Elected to STAAR's Board of Directors in June 2014; Serves as Chair of Recently Formed Quality & Regulatory Committee MO
Read more →STAASTAAR Surgical Reports Fourth Quarter and Full Year 2014 Results ~ Total Sales of $16.6 Million for Q4 and $75.0 Million for Full-Year 2014 ~ ~Full Year Sales Growth at 4%, 6% in Constant Currency~ ~Over 500,000 Visian I
STAAR Surgical Reports Fourth Quarter and Full Year 2014 Results ~ Total Sales of $16.6 Million for Q4 and $75.0 Million for Full-Year 2014 ~ ~Full Year Sales Growth at 4%, 6% in ~Over 500,000 Visian ICLs Successfully Implanted~ ~ Q4 GAAP Net Loss of $0.07 per Share, Non-
Read more →STAANASDAQ: STAA
1 NASDAQ: STAA November 20, 2014 Forward - Looking Statements All statements in this press release that are not statements of historical fact are forward - looking statements, including statements about any of the following: any projections of earnings, revenue, sales, profit ma
Read more →STAASTAAR Surgical Reports Third Quarter Results ~Total Sales Increase to $18.2M from $17.1M in Q3 2013; Up 9% on Constant Currency Basis~ ~ Visian ICL Sales of $10.6 Million versus $10.7 Million in Q3 2013 ~ ~ IOL Sales Gro
STAAR Surgical Reports Third Quarter ~Total Sales Increase to $18.2M from $17.1M in Q3 2013; Up 9% on Constant Currency Basis~ ~ Visian ICL Sales of $10.6 Million versus $10.7 Million in Q3 2013 ~ ~ IOL Sales Growth of 8.3%; Up 13% on Constant Currency Basis~ ~ GAAP Net Lo
Read more →STAALOUIS SILVERMAN APPOINTED TO STAAR SURGICAL BOARD OF DIRECTORS Appointment of Healthcare Industry Leader Expands STAAR's Board to Eight MONROVIA, CA
LOUIS SILVERMAN APPOINTED TO STAAR SURGICAL Appointment of Healthcare Industry Leader Expands STAAR's Board to Eight MONROVIA, CA, September 15, 2014 - STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery syst
Read more →STAATHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT STAA - Q2 2014 STAAR Surgical Co Earnings Call EVENT DATE/TIME: JULY 31, 2014 / 09:00PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 2014 Thomson Reu
THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT STAA - Q2 2014 STAAR Surgical Co Earnings Call EVENT DATE/TIME: JULY 31, 2014 / 09:00PM GMT Sherk EVC Group - IR Caldwell STAAR Surgical Company - President & CEO Brown STAAR Surgical Company - VP & CFO O'Brien William Blair & Co
Read more →STAASTAAR Surgical Reports 10% Second Quarter Revenue Growth ~Total Sales Increased to $20.0M from $18.2M in Q2 2013~ ~ Quarterly Visian ICL Sales Increased to $12.2 Million ~ ~ IOL Sales Growth of 10% Led by Increased Suppl
STAAR Surgical Reports 10% Second Quarter ~Total Sales Increased to $20.0M from ~ Quarterly Visian ICL Sales Increased to $12.2 Million ~ ~ IOL Sales Growth of 10% Led by Increased Supply of the KS-IOLs~ ~ GAAP Net Income Loss of $0.05 per Share~ MONROVIA, CA, July 30, 201
Read more →STAACAREN MASON ELECTED TO STAAR'S BOARD OF DIRECTORS ~Stockholders Approve All Proposals at Company Annual Meeting~ MONROVIA, CA
MASON ELECTED TO STAAR'S BOARD OF DIRECTORS ~Stockholders Approve All Proposals at Company Annual Meeting~ MONROVIA, CA, June 10, 2014 -- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the ey
Read more →STAAVisian ICL, Fastest Growing Refractive Technology in the World NASDAQ: STAA
1 Visian ICL, Fastest Growing Refractive Technology in the World NASDAQ: STAA May 7, 2014 Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including stateme nts about any of the followin
Read more →STAASTAAR Surgical Reports 12% First Quarter 2014 Revenue Growth ~Total Sales of $20.2M Increased 15% in Constant Currency from Q1 2013~ ~ Record Quarterly Visian ICL Sales Increased 15% to $12.2 Million ~ IOL Sales Increase
STAAR Surgical Reports 12% First Quarter ~Total Sales of $20.2M Increased 15% in Constant Currency from Q1 2013~ ~ Record Quarterly Visian ICL Sales Increased 15% to $12.2 Million ~ IOL Sales Increased 4%, Increased 12% in Constant Currency Conference Call and Video Webcas
Read more →STAAVisian ICL, Fastest Growing Refractive Technology in the World Non - Deal Roadshow April 2014 NASDAQ: STAA Forward - Looking Statements All statements in this presentation that are not statements of historical fact are f
Visian ICL, Fastest Growing Refractive Technology in the World Non - Deal Roadshow April 2014 NASDAQ: STAA Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including stateme nts about an
Read more →STAAVisian ICL, Fastest Growing Refractive Technology in the World Sidoti Eighteenth Annual Emerging Growth Conference
1 Visian ICL, Fastest Growing Refractive Technology in the World Sidoti Eighteenth Annual Emerging Growth Conference March 17, 2014 NASDAQ: STAA Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking stat
Read more →STAASTAAR Surgical Reports 15% Fourth Quarter Revenue Growth and 13% Full Year 2013 ~Total Sales Increased 22% in Constant Currency from Q4 2012~ ~ Record Quarterly Visian ICL Sales Increased to $11.5 Million~ ~ICL Revenue U
STAAR Surgical Reports 15% Fourth Quarter Revenue Growth and 13% Full Year 2013 ~Total Sales Increased 22% in Constant Currency from Q4 2012~ ~ Record Quarterly Visian ICL Sales Increased to $11.5 Million~ ~ICL Revenue Up 34% in APAC, 27% in EMEA Regions and 36% in North A
Read more →STAAKATHRYN TUNSTALL APPOINTED TO STAAR SURGICAL BOARD OF DIRECTORS Appointment Expands Board to Seven Members MONROVIA, CA
TUNSTALL APPOINTED TO STAAR SURGICAL Appointment Expands Board to Seven Members CA, January 30, 2014 -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced the appointment of Kathryn Tunstall
Read more →STAAVisian ICL, Fastest Growing Refractive Technology in the World January 2014 NASDAQ : STAA All statements in this presentation that are not statements of historical fact are forward - looking statements, including stateme
1 Visian ICL, Fastest Growing Refractive Technology in the World January 2014 NASDAQ : STAA All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following: any projections of earnin
Read more →STAAVisian ICL, Fastest Growing Refractive Technology in the World December 2013 NASDAQ : STAA All statements in this press release that are not statements of historical fact are forward - looking statements, including state
1 Visian ICL, Fastest Growing Refractive Technology in the World December 2013 NASDAQ : STAA All statements in this press release that are not statements of historical fact are forward - looking statements, including statem ents about any of the following: any projections of ear
Read more →STAASTAAR Surgical Reports Continued Momentum
STAAR Surgical Reports Continued Momentum During Third Quarter ~Total Sales of $17.1 Million Increased 8% from Q3 2012 / 14% Increase in Constant Currency~ ~Visian ICL Sales Grew 18%; Visian ICL with CentraFLOW Technology Driving Growth~ Revised Revenue Growth Metric of 13
Read more →STAAStephen P. Brown Appointed Chief Financial Officer at STAAR Surgical Company ~Deborah Andrews Becomes Vice President, Chief Accounting Officer ~ MONROVIA, CA
Stephen P. Brown Appointed Chief Financial Officer at STAAR Surgical Company ~Deborah Andrews Becomes Vice President, Chief Accounting Officer ~ MONROVIA, CA, September 9, 2013 -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implan
Read more →STAAVisian ICL, Fastest Growing Refractive Technology in the World
1 Visian ICL, Fastest Growing Refractive Technology in the World August 14, 2013 NASDAQ : STAA Forward - Looking Statements All statements in this press release that are not statements of historical fact are forward - looking statements, including statem ents about any of the fo
Read more →STAAInvestors Media EVC Group EVC Group Douglas Sherk, 415-652-9100 Chris Gale, 646-201-5431 Leigh Salvo, 415-568-9348 STAAR Surgical Reports Strong Second Quarter Financial Results Total Sales of $18.2 Million Incr
CONTACT: Investors Media EVC Group EVC Group Douglas Sherk, 415-652-9100 Chris Gale, 646-201-5431 Leigh Salvo, 415-568-9348 STAAR Surgical Reports Strong Second Quarter Financial Results Total Sales of $18.2 Million Increased 14% from Q2 2012 / 20% Increase on Constant Cu
Read more →STAASTAAR Surgical Gains Regulatory Approvals for Visian ICL with CentraFLOW Technology in Korea and Argentina ~ CentraFLOW Technology Driving Greater Adoption of the ICL Procedure ~ ~ Korea Currently Largest Market for ICL
STAAR Surgical Gains Regulatory Approvals for Visian ICL with CentraFLOW Technology in Korea and Argentina ~ CentraFLOW Technology Driving Greater Adoption of the ICL Procedure~ ~Korea Currently Largest Market for ICL Technology~ ~Argentina Market Key to Driving ICL Latin
Read more →STAANASDAQ : STAA Visian ICL, Fastest Growing Technology in the World May 2013 Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, inc
1 NASDAQ : STAA Visian ICL, Fastest Growing Technology in the World May 2013 Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including stateme nts about any of the following: any projec
Read more →STAASTAAR Surgical Reports Strong First Quarter 2013 Financial Results ~ Total Sales of $18 Million Increased 16% from Q1 2012 / 21% Increase on Constant Currency Basis~ ~ Visian ICL Sales Grew 24% to Record $10.6 Million ~
STAAR Surgical Reports Strong First Quarter 2013 Financial Results Sales of $18 Million Increased 16% from Q1 2012 / 21% Increase on Constant Currency Basis~ ~ Visian ICL Sales Grew 24% to Record $10.6 Million ~ ~nanoFLEX Toric IOL Launched ~ GAAP Net Income of $0.01 per sh
Read more →STAANASDAQ : STAA "Fastest Growing Refractive Technology in t he World" April 2013 Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements,
1 NASDAQ : STAA "Fastest Growing Refractive Technology in t he World" April 2013 Forward - Looking Statements All statements in this presentation that are not statements of historical fact are forward - looking statements, including stateme nts about any of the following: any pr
Read more →STAASTAAR SURGICAL PROVIDES PRELIMINARY FIRST QUARTER REVENUE RESULTS Visian ICL Revenue Increase Approximately 24%, a Record Quarterly High Total Revenue Increase Approximately 16% to $18 Million MONROVIA, CA
STAAR SURGICAL PROVIDES PRELIMINARY FIRST QUARTER REVENUE RESULTS Visian ICL Revenue Increase Approximately 24%, a Record Quarterly High Total Revenue Increase Approximately MONROVIA, CA, April 8, 2013 -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufactu
Read more →Competitive Position
How STAA ranks across every disease it competes inCompetitive Position is a premium feature
See how STAA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial